CMPD: AI 评分 60/100 — AI 分析 (4月 2026)

概要：

CMPD是做什么的？

CMPD的投资论点是什么？

CMPD在哪个行业运营？

CMPD有哪些增长机遇？

• Expansion of Mobile ECG and Ultrasound Solutions: CompuMed can capitalize on the growing demand for mobile healthcare solutions by expanding its mobile ECG and ultrasound services. The market for mobile medical devices is projected to reach substantial figures by 2028, driven by increased patient convenience and remote monitoring capabilities. By offering immediate access to board-certified specialists through mobile devices, CompuMed can attract a larger customer base and increase its revenue streams. This expansion requires investment in technology and marketing to reach a wider audience.
• Penetration of Underserved Markets: CompuMed has the opportunity to penetrate underserved markets such as rural healthcare facilities and correctional institutions. These markets often lack access to specialized medical expertise, creating a demand for telemedicine solutions. By partnering with rural hospitals and correctional facilities, CompuMed can provide telecardiology and teleradiology services to patients who would otherwise not have access to them. This expansion requires building relationships with key stakeholders and tailoring its services to meet the specific needs of these markets.
• Growth of OsteoGram Software: CompuMed's OsteoGram software, which aids in osteoporosis screening, diagnosis, and therapy monitoring, presents a significant growth opportunity. As the global population ages, the prevalence of osteoporosis is expected to increase, driving demand for diagnostic tools. By enhancing the capabilities of OsteoGram and marketing it to healthcare providers, CompuMed can capture a larger share of the osteoporosis screening market. This requires ongoing research and development to improve the software's accuracy and user-friendliness.
• Strategic Partnerships with Organ Procurement Organizations: CompuMed serves organ procurement organizations (OPOs), offering telemedicine solutions that can improve the efficiency and effectiveness of organ donation processes. By forming strategic partnerships with more OPOs, CompuMed can expand its reach and increase its revenue. Telemedicine can facilitate remote consultations and assessments, ensuring that organs are properly evaluated and allocated in a timely manner. This requires demonstrating the value of its services to OPOs and building strong relationships with key decision-makers.
• International Expansion: CompuMed has the potential to expand its services internationally, particularly in regions with limited access to specialized medical expertise. By targeting countries with developing healthcare systems, CompuMed can provide telecardiology and teleradiology services to a broader patient population. This expansion requires understanding the regulatory landscape and cultural nuances of each target market. It also requires building a network of local partners to facilitate service delivery and ensure compliance with local laws.

• Market Cap of $0.01 billion reflects its small size within the telemedicine industry.
• P/E ratio of -56.36 indicates the company is currently not profitable.
• Profit Margin of -1.8% shows the company is operating at a slight loss.
• Gross Margin of 46.8% suggests strong potential for profitability if operational costs are managed effectively.
• Beta of -0.29 indicates the stock is less volatile than the market.

CMPD提供哪些产品和服务？

• Provides telecardiology services, offering remote cardiac consultations and diagnostic interpretations.
• Offers teleradiology services, enabling remote radiological image analysis and reporting.
• Develops and markets OsteoGram software for osteoporosis screening and monitoring.
• Provides mobile ECG and ultrasound solutions for immediate access to specialists.
• Offers enterprise telemedicine solutions for medical facilities.
• Connects patients with U.S. Board-Certified specialists through cloud-based technology.
• Provides reading, transcription, reporting, and storage solutions for medical images.

CMPD如何赚钱？

• Fee-for-service model: Charging medical facilities and healthcare providers for telecardiology and teleradiology consultations.
• Software licensing: Generating revenue from licensing the OsteoGram software to healthcare providers.
• Subscription-based services: Offering subscription packages for ongoing access to telemedicine services and support.
• Medical device sales: Selling ECG devices and ultrasound equipment to medical facilities and patients.

• Hospitals and medical centers seeking to expand their service offerings.
• Rural healthcare facilities lacking on-site specialists.
• Organ procurement organizations requiring efficient remote assessments.
• Correctional healthcare facilities providing medical care to inmates.

• Specialized Expertise: Focus on telecardiology and teleradiology provides a niche advantage.
• Cloud-Based Technology: Proprietary platform enables efficient and secure remote consultations.
• Established Network: Existing relationships with U.S. Board-Certified specialists.
• OsteoGram Software: Unique software offering for osteoporosis screening and monitoring.

什么因素可能推动CMPD股价上涨？

• Upcoming: Expansion of mobile ECG and ultrasound solutions into new geographic markets.
• Ongoing: Strategic partnerships with rural healthcare facilities to provide telemedicine services.
• Ongoing: Development and marketing of enhanced OsteoGram software for osteoporosis screening.
• Upcoming: Potential regulatory changes favoring telemedicine reimbursement.
• Ongoing: Increasing adoption of telemedicine due to rising healthcare costs and aging populations.

CMPD的主要风险是什么？

• Potential: Intense competition from larger telemedicine providers with greater financial resources.
• Potential: Cybersecurity breaches compromising patient data and disrupting services.
• Ongoing: Limited financial resources and negative profitability impacting growth prospects.
• Potential: Economic downturn reducing healthcare spending and demand for telemedicine services.
• Ongoing: Regulatory hurdles and compliance requirements in different geographic markets.

CMPD的核心优势是什么？

• Specialized expertise in telecardiology and teleradiology.
• Cloud-based technology platform for efficient remote consultations.
• Established network of U.S. Board-Certified specialists.
• Proprietary OsteoGram software for osteoporosis screening.

CMPD的劣势是什么？

• Small market capitalization and limited financial resources.
• Negative P/E ratio and profit margin.
• High dependence on a small number of key customers.
• Limited brand recognition compared to larger competitors.

CMPD有哪些机遇？

• Expansion into underserved markets such as rural healthcare and correctional facilities.
• Growth of mobile ECG and ultrasound solutions.
• Increased adoption of telemedicine due to COVID-19 pandemic.
• Strategic partnerships with organ procurement organizations.

CMPD面临哪些威胁？

• Intense competition from larger telemedicine providers.
• Regulatory changes affecting telemedicine reimbursement.
• Cybersecurity risks associated with cloud-based technology.
• Economic downturn impacting healthcare spending.

CMPD的竞争对手是谁？

• Cloudbreak Health — Focuses on video remote interpreting for healthcare. — (CLABF)
• CloudMD Software & Services Inc. — Provides a range of virtual healthcare solutions. — (CNGGF)
• CPM Medical Consultants — Offers medical consulting and review services. — (CPMV)
• Dogness International Corporation — Primarily focused on pet products with limited overlap. — (DOGP)
• Fnampt AG — Provides IT solutions for healthcare. — (FNAM)

Key Metrics

• MoonshotScore: 60/100

Company Profile

• CEO: Lee Keddie
• Headquarters: Los Angeles, US
• Employees: 8
• Founded: 1987

AI Insight

• OTC Tier: OTC Other
• Disclosure Status: Unknown